Medial EarlySign provides an advanced AI-based algorithm platform that leverages routine blood test results, common labs and EHR data to stratify populations, optimize care, and help prevent or delay serious health conditions. The platform is already in clinical practice and has been supported by peer-reviewed research published by organizations and hospitals including Kaiser Permanente, Oxford University and Maccabi Healthcare Services. The company is developing a suite of AlgoMarker™ stratification models addressing cancers, diabetes, associated complications and other life-threatening conditions. Medial EarlySign plans to use new funding to broaden its suite of solutions and to expand clinical research and global implementations of its clinically-supported technology. Financially, the company completed a $30M Series B that brings total funding to $50M.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2018